Merck & Company, Inc. Price Today
Merck & Company, Inc.
MRK
Healthcare
$266.43B
💰
Market Cap
20.5
💸
Price to Earnings
$5.1
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
15 |
Strong Buy |
9 |
Hold |
9 |
Sell |
0 |
Strong Sell |
0 |
MRK Price Forecast Target
105.0 👉 122.4 +17%
MRK EPS Forecast
5.1 👉 7.7 +50%
Financials
Profit Margin
5 %
Revenue Growth
3.0 %
Dividend
$ 2.92
Held Percent
0.1% - Insiders
77.6% - Institutions
22.3% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $26.0B
-
💰 Blackrock Inc. $22.2B
-
💰 State Street Corporation $12.4B
-
💰 Wellington Management Group, LLP $7.3B
-
💰 Geode Capital Management, LLC $5.4B
Stock Ideas
Daniel Loeb Portfolio
Daniel Loeb is an American billionaire businessman and founder/CEO of Third Point LLC, a global investment firm managing over $12 billion in assets through long/short equity investments and activism. As one of the world's most successful hedge fund…
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Chase Coleman Portfolio
Chase Coleman, the young and accomplished founder of Tiger Global, has made a significant impact in the investment world. With initial funding from Julian Robertson, Coleman's Tiger Global Management delivered impressive returns, including a remarka…📮FAQ
Some Frequently Asked Questions.
The Merck & Company, Inc. industry is Drug Manufacturers—General
The Merck & Company, Inc. sector is Healthcare
The Merck & Company, Inc. forecasted predicted Price to Earnings PE ratio is 13.7
The Merck & Company, Inc. Price to Earnings PE ratio is 20.5
The Market Capitalization of Merck & Company, Inc. is $266.43B
There are total of 2534441780 float shares with 77.6% held by Institutions and 0.1% held by insiders
The MMerck & Company, Inc. forecasted Earnings per Share EPS is $7.7
The Merck & Company, Inc. Earnings per Share EPS is 5.1
The Merck & Company, Inc. company has $42077000000 gross profits with 5 profit margins
The Merck & Company, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Merck & Company, Inc. Revenue is $58311000064 with 0.03 revenue growth
The price target for Merck & Company, Inc. stock is $122.4 for the high target and $99.8 for the low target
The consensus analyst recommendations for Merck & Company, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Merck & Company, Inc. is Buy, with the following breakdown:
- Buy: 15
- Strong Buy: 9
- Hold: 9
- Sell: 0
- Strong Sell: 0
The Beta of Merck & Company, Inc. is 0.3
The dividend of Merck & Company, Inc. is $2.92
The dividend yield of Merck & Company, Inc. is 0.0278%
The biggest institutional and mutual fund holders of Merck & Company, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- State Street Corporation
- Wellington Management Group, LLP
The Merck & Company, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0